^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ZG16B expression

    i
    Other names: ZG16B, Zymogen Granule Protein 16B, HRPE773, PRO1567, JCLN2, Jacalin-Like Lectin Domain Containing 2, Zymogen Granule Protein 16 Homolog B, Pancreatic Adenocarcinoma Upregulated Factor, Zymogen Granule Protein 16 Homolog B (Rat), Endocrine And Exocrine Protein, EECP, PAUF
    Entrez ID:
    124220
    Related biomarkers:
    Expression
    1year
    Zymogen granule protein 16B (ZG16B) is a druggable epigenetic target to modulate the mammary extracellular matrix. (PubMed, Cancer Sci)
    We found that in non-malignant mammary epithelial cells the combination of the chemopreventive agents bexarotene (Bex) and carvedilol (Carv) suppresses the zymogen granule protein 16B (ZG16B, PAUF) through an interaction of ARID1A with a proximal enhancer. In contrast, Bex + Carv inhibited colony formation, reduced Ki67 levels, ZG16B expression and glucose uptake in MDA-MB231 xenografts. These data establish ZG16B as a druggable pro-tumorigenic target in breast cell transformation and suggest a key role of the matrisome network in rexinoid-dependent antitumor activity.
    Journal
    |
    ARID1A (AT-rich interaction domain 1A) • ZG16B (Zymogen Granule Protein 16B)
    |
    ZG16B expression
    |
    Targretin oral (bexarotene oral)